Automated and rapid detection of cancer in suspicious axillary lymph nodes in patients with breast cancer

التفاصيل البيبلوغرافية
العنوان: Automated and rapid detection of cancer in suspicious axillary lymph nodes in patients with breast cancer
المؤلفون: Neesha Venkatesan, Jingping Yuan, Suzana Tulac, Chuang Chen, Mary Jo Fackler, Bradley M. Downs, Chuan gui Song, Juanjuan Li, Yufei Liu, Kejing Zhang, Timothy de Guzman, Leslie Cope, Xiuyun Zhang, Christopher J. VandenBussche, Saraswati Sukumar, Yong Han, Edwin W. Lai
المصدر: NPJ Breast Cancer
npj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
بيانات النشر: Springer Science and Business Media LLC, 2021.
سنة النشر: 2021
مصطلحات موضوعية: 0301 basic medicine, medicine.medical_specialty, Axillary lymph nodes, Sentinel lymph node, Article, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Cytology, Biopsy, medicine, Pharmacology (medical), Radiology, Nuclear Medicine and imaging, Prospective cohort study, RC254-282, medicine.diagnostic_test, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Cancer, Diagnostic markers, medicine.disease, 030104 developmental biology, Fine-needle aspiration, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Radiology, business, Biomarkers
الوصف: Preoperative staging of suspicious axillary lymph nodes (ALNs) allows patients to be triaged to ALN dissection or to sentinel lymph node biopsy (SLNB). Ultrasound-guided fine needle aspiration (FNA) and cytology of ALN is moderately sensitive but its clinical utility relies heavily on the cytologist’s experience. We proposed that the 5-h automated GeneXpert system-based prototype breast cancer detection assay (BCDA) that quantitatively measures DNA methylation in ten tumor-specific gene markers could provide a facile, accurate test for detecting cancer in FNA of enlarged lymph nodes. We validated the assay in ALN-FNA samples from a prospective study of patients (N = 230) undergoing SLNB. In a blinded analysis of 218 evaluable LN-FNAs from 108 malignant and 110 benign LNs by histology, BCDA displayed a sensitivity of 90.7% and specificity of 99.1%, achieving an area under the ROC curve, AUC of 0.958 (95% CI: 0.928–0.989; P N = 72, benign, N = 53 by cytology) collected in the outpatient setting prior to neoadjuvant chemotherapy (NAC). Using the ROC-threshold determined in the prospective study, compared to cytology, BCDA achieved a sensitivity of 94.4% and a specificity of 92.5% with a ROC-AUC = 0.977 (95% CI: 0.953–1.000; P
تدمد: 2374-4677
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f9f52cfecaa3fbd896bee1e21346cb1Test
https://doi.org/10.1038/s41523-021-00298-6Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....8f9f52cfecaa3fbd896bee1e21346cb1
قاعدة البيانات: OpenAIRE